In-depth Study—Tumor Sequencing Industry
The 21st century has been the century of biology, because of the improvement of people's living
standards and the settlement of living problems. It also gave power to the health industry, and
made it a sunrise industry forever.
Tumor sequencing is going to rise.
Gene mutation Catalyzes Tumor Formation
Human cell genes contain proto-oncogenes and tumor suppressor genes. Proto-oncogene is a gene
that is involved in cell proliferation and is highly conserved in evolution. When this type of gene
mutates, it can improve the function of the gene and increase the product, which makes the cell
proliferate and form the tumor.
Tumor suppressor genes, also known as anti-oncogenes, have the function of inhibiting cell
proliferation in normal cells. When this type of gene mutates or its structure changes, its functions
will be reduced or missing, and thus not capable of controlling the cell development, cell growth
as well as cell differentiation and regulation. Under this circumstance, the cells will proliferate
excessively, after which tumors will also be formed.
Tumors are Classified by Gene Mutations
Tumor is of great heterogeneity. Although patients may have the same type of tumor, gene
mutations within the tumor cells that cause the disease may be far different. Therefore, the cancer
cells in tumors are likely to have heterogeneity in functions.
Take non-small cell lung cancer as an example. Currently, it is found that about 25% of the
patients have mutations of gene KRAS. While, other patients also have different mutations that
lead to the mutation of common drive genes, including epidermal growth factor receptor (EGFR),
anaplastic lymphoma kinase (ALK), V-RAF murine sarcoma virus proto-oncogene B1 (BRAF)
gene, epidermal growth factor receptor 2 (HER2), etc.
For different individuals of mutant genes, there should be different targeted drugs and treatment
strategies. We now already have successful cases in practical application. Dr. Nader Javadi is a
leading tumor specialist in the forefront of "precision medical".
He once treated patients (He accepted 25 such patients in 2014) who have been gave up by
well-known cancer centers (including Anderson Cancer Center, Cedars-Sinai Medical Center and
so on) with phase iv (late stage) cancer using corresponding precise treatment based on different
tumor specific genomic lesions of different patients. Only three months later, all patients lived
longer than expected. Cancer cells in most of them decreased by 40％ to 60％, some even
decreased by 90％.
